Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway-Reference-Cited by-同舟云学术

Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway

Published:2018-12-07 Issue:14 Volume:38 Page:2516-2532
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Yang Zhan,Qu Chang-Bao,Zhang Yong,Zhang Wen-Feng,Wang Dan-Dan,Gao Chun-Cheng,Ma Long,Chen Jin-Suo,Liu Kai-Long,Zheng Bin,Zhang Xin-Hua,Zhang Man-Li,Wang Xiao-Lu,Wen Jin-Kun,Li Wei

Funder

The National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-018-0602-8.pdf

Reference54 articles.

1. Wetherill YB, Hess-Wilson JK, Comstock CE, Shah SA, Buncher CR, Sallans L, et al. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther. 2006;5:3181–90.

2. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006;99:333–44.

3. Matsumoto A, Inoue A, Yokoi S, Nozumi K, Miyazaki K, Hosoki S, et al. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int J Urol. 2009;16:687–91.